PeptiDream Inc.
4587.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$138.13B
Close$
$1435.64
33.5% upside
Current Fair Value
33.5% upsideUndervalued by 33.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $138.13 Billion |
|---|---|
| Enterprise Value | $130.86 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-28.99 |
| Beta | 0.35 |
| Outstanding Shares | 128,567,724 |
Return
| Return on Equity | -7.55% |
|---|---|
| Return on Assets | -5.07% |
| Return on Invested Capital | -7.58% |
Valuation & Multiples
| P/E Ratio | -38.24 |
|---|---|
| PEG | -0.26 |
| Price to Sales | 7.21 |
| Price to Book Ratio | 2.87 |
| Enterprise Value to Revenue | 6.79 |
| Enterprise Value to EBIT | -27.05 |
| Enterprise Value to Net Income | -36 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-3.12
Average shareholder expectationRevenue Estimate
$5.68 B
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-7.08
Average shareholder expectationRevenue Estimate
$5.06 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PeptiDream Inc.
763 employees
CEO: Patrick Crawford Reid PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique pr...